Physician profile
Mitchell A Ayers
NPI 1770019937
$624.31
in general payments reported to CMS, 2019-2025
18 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.38 · 2024: $198 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $150.02 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $59.16 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $52.84 | 2025 | Airsupra |
| Abbvie INC. | $40.45 | 2024-2025 | |
| Novo Nordisk INC | $35.40 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $33.39 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $33.27 | 2025 | Symplicity G3 |
| Otsuka America Pharmaceutical, INC. | $28.52 | 2025 | Rexulti |
| Seqirus USA INC | $25.42 | 2025 | Fluad, Flucelvax |
| Astellas Pharma US INC | $22.38 | 2023 | Veozah |
| Galderma Laboratories, L.P. | $22.31 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.23 | 2025 | Xifaxan |
| Insulet Corporation | $21.20 | 2024 | Omnipod |
| Esperion Therapeutics, INC. | $18.71 | 2025 | Nexletol |
| Pfizer INC. | $17.84 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $14.97 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $14.49 | 2025 | Vaxneuvance, Enflonsia, Capvaxive |
| Organon LLC | $12.71 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.